证券代码：301363 证券简称：美好医疗 公告编号：2025-046 深圳市美好创亿医疗科技股份有限公司 第二届监事会第十六次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 具体内容详见公司于同日在巨潮资讯网（www.cninfo.com.cn）披露的相关 公告。 表决结果：同意 3 票，反对 0 票，弃权 0 票。 本议案尚需提交公司 2025 年第一次临时股东大会审议。 三、备查文件 1、公司第二届监事会第十六次会议决议。 一、监事会会议召开情况 深圳市美好创亿医疗科技股份有限公司（以下简称"公司"）第二届监事会 第十六次会议通知于2025年7月21日以书面、电话等方式送达全体监事，并于2025 年7月24日在公司会议室召开现场会议。本次会议由监事会主席黎莎女士主持， 会议应到监事3人，实到监事3人，会议的召集和召开符合《中华人民共和国公司 法》《公司章程》等相关规定。 二、监事会会议审议情况 经全体与会监事认真审议、充分讨论，会议审议并通过了以下议案： （一）审议通过《关于调整公司及控股子公司预计担保额度的议案》 经审核，监事会认为：本次 ...

本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 深圳市美好创亿医疗科技股份有限公司（以下简称"公司"）第二届董事会 第十九次会议通知于 2025 年 7 月 21 日以书面、电子邮件及电话等方式送达全体 董事，并于 2025 年 7 月 24 日在公司会议室以现场结合通讯方式召开。会议应参 加董事 9 人，实际参会董事 9 人，其中 Florian Then 先生、Joel Chan 先生、 王建新先生、梁永晔先生、吴学斌先生、孙超先生以通讯方式参会。本次会议由 董事长熊小川先生召集并主持。经全体与会董事确认，本次会议的召集、召开以 及审议程序符合《公司法》《公司章程》和《董事会议事规则》等有关规定，会 议形成的决议合法、有效。 二、董事会会议审议情况 经全体与会董事认真审议、充分讨论，会议审议并通过了以下议案： （一）审议通过《关于调整公司及控股子公司预计担保额度的议案》 根据公司及子公司战略发展规划及生产经营需要，董事会同意增加担保对象 并调整公司及控股子公司向全资子公司提供的预计担保额度，累计提供最高不超 过人民币18亿元或等值外 ...

证券代码：301363 证券简称：美好医疗 公告编号：2025-047 深圳市美好创亿医疗科技股份有限公司 关于调整公司及控股子公司预计担保额度的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、预计担保额度调整情况 深圳市美好创亿医疗科技股份有限公司（以下简称"公司"或"美好医疗"） 于2025年4月16日召开第二届董事会第十六次会议及第二届监事会第十三次会 议，于2025年5月8日召开2024年年度股东大会，分别审议通过了《关于公司及控 股子公司向银行等金融机构申请授信额度暨担保额度预计的议案》。同意公司及 控股子公司为公司的全资子公司惠州市美好创亿医疗科技有限公司（以下简称 "惠州美好"）提供不超过人民币3亿元或等值外币金额的担保、为美好医疗（马 来西亚）有限公司（以下简称"马来美好"）提供不超过人民币2亿元或等值外 币金额的担保、为米曼（马来西亚）有限公司（以下简称"马来米曼"）提供不 超过人民币5亿元或等值外币金额的担保，累计提供最高不超过人民币10亿元或 等值外币金额的担保。具体内容详见公司于2025年4月18日在巨潮资讯网 （www.cn ...

证券代码：301363 证券简称：美好医疗 公告编号：2025-048 深圳市美好创亿医疗科技股份有限公司 关于召开2025年第一次临时股东大会的通知 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 深圳市美好创亿医疗科技股份有限公司（以下简称"公司"）第二届董事会第 十九次会议决定于2025年8月11日（星期一）下午15:30召开2025年第一次临时股东 大会（以下简称"本次股东大会"），本次股东大会采取现场投票和网络投票相结合 的方式召开，现将有关事项提示如下： 一、召开会议的基本情况 1.股东大会届次：2025年第一次临时股东大会 2.股东大会的召集人：公司董事会 3.会议召开的合法、合规性：本次会议召开符合有关法律、行政法规、部门规 章、规范性文件、深圳证券交易所业务规则和《公司章程》等的规定。 4.会议召开的日期、时间 （1）现场会议时间：2025年8月11日（星期一）下午15:30 （2）网络投票时间：2025年8月11日（星期一）。其中，通过深圳证券交易所交 易系统进行网络投票的时间为2025年8月11日上午9:15-9:25、9:30-11:3 ...

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Meihao Medical, indicating a decline in stock price and a relatively low PE ratio compared to the industry average [1][2] - As of the first quarter of 2025, Meihao Medical reported a revenue of 296 million yuan, reflecting a year-on-year increase of 5.05%, while net profit decreased by 10.62% to 51.875 million yuan [1] - The company operates in the medical device sector, focusing on the design, development, manufacturing, and sales of precision components and products, including home ventilator components and cochlear implant components [1] Group 2 - Meihao Medical's current PE ratio stands at 29.89, significantly lower than the industry average of 53.52 and the median of 37.14, ranking it 60th in the industry [2] - The total market capitalization of Meihao Medical is approximately 10.689 billion yuan, with 18 institutions holding a total of 17.6063 million shares valued at 311 million yuan [1][2] - The company is recognized as a national high-tech enterprise and a Guangdong provincial manufacturing champion, indicating its competitive position within the industry [1]

Core Viewpoint - The article discusses the performance and management of the Rongtong Health Industry Flexible Allocation Mixed Fund A/B, highlighting its net asset growth and the background of its fund manager, Wan Minyuan [1][2]. Fund Performance - As of June 30, 2025, the net assets of the Rongtong Health Industry Flexible Allocation Mixed Fund A/B reached 2.074 billion yuan, reflecting a 1.92% increase from the previous period [1]. - The fund's recent performance includes a 15.0% return over the last three months and a 19.86% return over the past year, with a cumulative return of 166.1% since inception [2]. Fund Manager Background - Wan Minyuan, the fund manager, holds a PhD in Biomedical Science from Sichuan University and has extensive experience in the investment sector, having worked at various securities firms and investment management companies since 2011 [1]. Fund Holdings - The top ten stock holdings of the fund include Yixin Tang, Aibo Medical, Sanyou Medical, Jianzhijia, Kaili Medical, Yangguang Nuohuo, Dongfang Biological, Puri Eye Care, Meihua Medical, and Meinian Health, with a combined holding percentage of 57.00% [2]. Company Overview - Rongtong Fund Management Co., Ltd. was established in May 2001 and is based in Shenzhen, focusing on capital market services, with a registered capital of 125 million yuan [2].

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Meihao Medical, which closed at 18.72 yuan, up 3.83%, with a rolling PE ratio of 29.78, marking a new low in 28 days, and a total market capitalization of 10.649 billion yuan [1] - In comparison to the industry, Meihao Medical's PE ratio of 29.78 is significantly lower than the average PE ratio of 52.06 and the median of 37.22 within the medical device sector, ranking 66th among its peers [1][2] - As of June 30, 2025, Meihao Medical had 12,487 shareholders, an increase of 119 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares per shareholder [1] Group 2 - Meihao Medical specializes in the design, development, manufacturing, and sales of precision components and products for medical devices, including home ventilator components and cochlear implant components [1] - The latest quarterly report for Q1 2025 shows that the company achieved a revenue of 296 million yuan, a year-on-year increase of 5.05%, while net profit was 51.875 million yuan, reflecting a year-on-year decrease of 10.62%, with a gross profit margin of 39.28% [1]

Group 1 - The human brain engineering sector experienced a slight increase of 0.41% on July 11, with a total capital outflow of 583.41 million [1] - A total of 21 stocks in the sector rose, while 8 stocks declined [1] - The top-performing stocks included Meihao Medical (+3.83%), Hanwei Technology (+2.72%), and Zhongke Information (+2.27%) [1] Group 2 - The stocks with the largest declines were ST Huatuo (-3.87%), Pulite (-1.94%), and Aipeng Medical (-1.72%) [1] - The overall market sentiment showed a mixed performance with significant capital movements in both rising and falling stocks [1]

Core Viewpoint - The company, 美好医疗, is focusing on advanced technologies and automation in the medical device sector, responding to market demands and trends in healthcare, particularly in the context of an aging population and increasing healthcare expenditures [2]. Group 1: Company Developments - As of July 8, 2025, 美好医疗's stock closed at 18.17 yuan, down 0.27%, with a turnover rate of 5.0%, a trading volume of 78,100 shares, and a transaction value of 141 million yuan [1]. - The company has established an open R&D innovation platform that utilizes both modular and specialized technology to enhance its product offerings in various medical device segments, including respiratory health and cardiovascular care [2]. - The company is actively integrating automation and intelligent manufacturing technologies, including the development of hundreds of non-standard automation projects and the application of robotic process automation (RPA) in various business processes [2]. Group 2: Market Context - The medical device industry is closely linked to the aging population, with increasing healthcare spending globally, which provides a favorable environment for the company's long-term growth [2]. - The company is responding to the significant domestic elderly care market by providing comprehensive services from product development to mass delivery in the medical device sector [2]. - The company is expanding its product line, including the "美好笔" insulin injection pen, which is expected to contribute to revenue growth in the coming years [2]. Group 3: Investor Relations - The company has acknowledged the fluctuations in its stock price, which has fallen below its initial public offering price of 30.66 yuan, and has indicated that it is focused on strategic development and maintaining strong customer relationships [2]. - The company plans to release its half-year report on August 19, 2025, providing further insights into its financial performance and strategic direction [2]. Group 4: Trading Information - On July 8, 2025, the net outflow of main funds was 706.11 million yuan, while retail investors saw a net inflow of 591.99 million yuan [3][4].

Company Overview - Meihua Medical closed at 18.05 yuan, up 1.69%, with a rolling PE ratio of 28.71 times and a total market value of 10.268 billion yuan [1] - The company ranks 65th in the medical device industry, which has an average PE ratio of 51.05 times and a median of 36.62 times [1] - As of the first quarter of 2025, 30 institutions held shares in Meihua Medical, including 24 funds, 4 others, and 2 insurance companies, with a total holding of 42.1394 million shares valued at 1.23 billion yuan [1] Business Operations - Meihua Medical specializes in the design, development, manufacturing, and sales of precision components and products for medical devices [1] - The main products include home respiratory machine components, artificial cochlear components, other medical product components, precision molds, automation equipment, and home and consumer electronics components [1] - The company is recognized as a national high-tech enterprise and a national intellectual property advantage enterprise, as well as a champion in a specific manufacturing sector in Guangdong Province [1] Financial Performance - In the first quarter of 2025, Meihua Medical achieved an operating income of 296 million yuan, a year-on-year increase of 5.05% [1] - The net profit for the same period was 51.875 million yuan, reflecting a year-on-year decrease of 10.62% [1] - The sales gross margin stood at 39.28% [1]